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reatment of Stent Restenosis
oving Beyond Momentum*
arold L. Dauerman, MD, FACC
urlington, Vermont
he journey taken for treatment of in-stent restenosis (ISR)
egan similarly to and then diverged markedly from the
ath traveled for de novo lesions. Similar to de novo lesions,
alloon angioplasty initially demonstrated safety and mod-
rate success rates for treatment of ISR (1). With more
hallenging lesions (i.e., diffuse ISR), though, balloon an-
ioplasty proved to be far from adequate (Fig. 1) (2,3). For
oth ISR and de novo lesions, a geometric model of
reatment success was embraced (4): Optimization of final
umen diameter became the goal. Registry studies suggested
potential geometric benefit for debulking before angio-
lasty for both de novo and ISR lesions (5,6). Thus,
nterventional cardiologists embraced a variety of atherec-
omy techniques (7,8) to optimize final lumen diameter
uring ISR treatment. Although these options appeared to
mprove lumen diameters and recurrence rates in registry
tudies of ISR, they failed to establish superiority in the
etting of multiple operators participating in randomized
linical trials (9–11).
See page 2152
Stent restenosis therapy headed down its own road
ollowing pivotal brachytherapy trials that demonstrated
enefit among patients with ISR but not with de novo
esions (12–15). Treatment of de novo lesions focused on
ptimization of final lumen diameter with stents. On the
ther hand, attempts to treat restenotic lesions with further
mplantation of bare metal stents did not show improved
utcomes compared with balloon angioplasty (11). Thus,
ve years ago, treatment of de novo lesions (bare-metal
tents to optimize lumen diameter) and restenotic lesions
brachytherapy to reduce late loss) followed divergent paths
n interventional cardiology.
RUG-ELUTING STENTS (DES)
OR TREATMENT OF ISR
rachytherapy has practical limitations, efficacy concerns,
nd safety issues (12). Thus, the opportunity for both de
ovo and restenotic lesions to converge again with the
impler DES-based inhibition of late loss was embraced
fter approval of DES for de novo lesions (16). Rapid
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the University of Vermont College of Medicine, Burlington, Vermont.doption of DES for such high-risk groups represented
omentum and encouraging registry findings (17), but
andomized superiority of DES to other therapies in en-
iched higher-risk populations had yet to be established. In
his issue of the Journal, the Restenosis Intrastent: Balloon
ngioplasty Versus Elective Sirolimus-Eluting Stent Im-
lantation (RIBS-II) trial moves us beyond momentum by
onfirming superiority for sirolimus DES compared with
alloon angioplasty for the treatment of patients with ISR
Fig. 1) (18). Although the study sample is strikingly small
n  150) compared with the phase III clinical trials of
ES (n 1,000), the enriched population of high-risk
atients allows for meaningful comparisons of clinical end
oints.
This study amplifies the findings of the randomized
ntracoronary Stenting with Antithrombotic Regimen–
rug-Eluting Stents for In-Stent Restenosis (ISAR-
ESIRE) trial (19). In both studies, DES is associated with
greater than 50% reduction in recurrent restenosis com-
ared with balloon angioplasty. In the RIBS-II trial, we see
he true convergence of de novo and ISR therapies via
echanistic insights from the intravascular ultrasound sub-
tudy. Namely, the mechanism of benefit of DES for ISR is
he same as DES for de novo lesions: Stents improve acute
ain compared with angioplasty (a geometric benefit [4]),
nd the drug/polymer combination minimizes late loss (16).
lthough both the ISAR-DESIRE and RIBS-II studies
ompared DES to a less effective therapy (balloon angio-
lasty) for ISR, DES for ISR is still superior when com-
ared to the gold standard of brachytherapy (20). Thus,
here is no convincing argument to sway operators to the
ivergent path of brachytherapy. Finally, the benefits of
ES for ISR extend to even lower-risk ISR subgroups (i.e.,
ocal lesions) that might have favored angioplasty alone (3).
Practical questions arise from the RIBS-II and ISAR-
ESIRE studies:
The randomized population for both studies had ISR of
bare metal stents. Currently, the vast majority of ISR will
be related to DES failure in increasingly complex lesion
types (21). Will DES failures be more resistant than bare
metal stents to reimplantation with DES?
The benefit of brachytherapy as compared to balloon
angioplasty is diluted over five-year follow-up (12).
Given that both DES and brachytherapy similarly share
inhibition of late loss as the mechanism of benefit, are
six-month (ISAR-DESIRE) and one-year (RIBS-II)
end points conclusive?
The RIBS-II protocol required 12 atm inflation for
repeat stenting, although the average deployment pres-
sure was 15.8  2.9 atm. Caution may be warranted in
extending these excellent outcomes to a strategy of lower
pressure deployment; concern about stent underexpan-
sion is warranted when dealing with multiple layers of
stent and polymer (22).
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Editorial Comment June 6, 2006:2161–3If DES failure occurs in a sirolimus-eluting stent, is this
a marker for a specific drug resistance favoring reimplan-
tation with a non–sirolimus-eluting stent?
Finally, what role does adjunctive pharmacology have
with respect to restenosis outcomes? The similar and
marked systemic inflammatory response after both bare-
metal and drug-eluting stenting (23) suggests that the
benefit of DES for ISR is entirely local; therefore,
systemic pharmacotherapy is unlikely to have a major role
in further improving restenosis rates.
OVING BEYOND MOMENTUM
andmark trials in lower-risk lesions defined the beginning
f a new DES era (16). A leap of faith occurred as we
mbraced a nearly universal application of drug-eluting
tenting (17) based on the simplicity of the technique and its
arked potential to improve patient outcomes. Like other
andomized DES trials involving higher risk patients (24),
he RIBS-II study moves us firmly beyond the beginning of
he drug eluting stent era. We are now beyond momentum
lone as a justification for higher-risk applications of drug-
luting stenting. As we look now toward the challenges of
ur DES middle age, we need not necessarily discard our
outhful exuberance (“no more restenosis, no more sur-
eons”). Rather, we have defined a successful model for
valuating this single convergent standard of care—DES to
imply optimize acute gain and minimize late loss. As with
reatment of stent restenosis, momentum must be justified
y well designed randomized studies in high-risk popula-
igure 1. Randomized clinical trials of treatment options for in-stent r
rug-eluting stents as a treatment of in-stent restenosis. ARTIST (9)  A
estenosis Trial; BMS  bare metal stent; ISAR-DESIRE (19)  Int
n-Stent Restenosis; PES  paclitaxel-eluting stent; RESCUT (10)  Res
alloon Angioplasty Versus Elective Bare Metal Stenting; RIBS II (18) 
tenting; SES sirolimus-eluting stent; START (15) Sr90 Treatment o
estenosis Trial.ions (i.e., diabetics with multivessel disease, bifurcationesions, and prevention of infarction) in order to confirm our
ontinuing, if no longer youthful, exuberance.
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